XLRN News and Press, Acceleron Pharma Inc. From 04/03/20

Acceleron Pharma (NASDAQ: XLRN ) and collaboration partner Bristol-Myers Squibb (NYSE: BMY ) announce the FDA nod for Reblozyl (luspatercept-aamt) for the treatment of anemia in certain adult patients with very low-to-intermediate-risk myelodysplastic syndromes who have failed treatment wi...

The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) transfusions and have failed an erythropoiesis stimulating agent Reblozyl regulates late-stage RBC maturation to relie...

Investing in biotech can be volatile during "normal" market conditions. Today's COVID-19 impacted economy amplifies that volatility and in the process, it's making good companies substantially cheaper than a few months ago. Here two biotechs, one large and one small, battle it out to win in...

Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...

Bristol-Myers Squibb (NYSE: BMY ) and Acceleron Pharma (NASDAQ: XLRN ) announce that the New England Journal of Medicine has published results from BELIEVE, the Phase 3 study evaluating the safety and efficacy of Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with beta ...

Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the New...

Healthcare Pulse A new reality dawned as the stock market entered a bear market. It wasn't a tiptoe moment for the bear. The market simply plummeted into a bear market canyon. Just from March 4 to March 12, in about a week, the S&P 500 and Nasdaq declined 20% or more. The healthcare ...

Acceleron Pharma (NASDAQ: XLRN ) has decided to terminate development of ACE-083 after a Phase 2 study in patients with  Charcot-Marie-Tooth disease, a group of inherited disorders that cause nerve damage, failed to demonstrate functional improvement despite meeting the primary...

– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 – Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discove...

Acceleron Pharma, Inc. (XLRN) Q4 2019 Earnings Conference Call February 27, 2020 5:00 PM ET Company Participants Todd James - Senior Vice President, Corporate affairs and Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Sujay K...